Amneal Pharmaceuticals, Inc. AMRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $722.52M-11.3% | $814.32M+3.8% | $784.51M+8.3% | $724.51M+4.2% | $695.42M-4.8% | ||
| $402.41M-22.2% | $517.13M+1.3% | $510.54M+16.5% | $438.26M-0.3% | $439.53M-6.0% | ||
| $320.11M+7.7% | $297.19M+8.5% | $273.97M-4.3% | $286.25M+11.9% | $255.89M-2.7% | ||
| 44.3%+7.8pp | 36.5%+1.6pp | 34.9%-4.6pp | 39.5%+2.7pp | 36.8%+0.8pp | ||
| $38.38M+10.2% | $34.82M-45.0% | $63.35M+32.1% | $47.96M+19.8% | $40.04M-26.2% | ||
| $138.86M-5.2% | $146.46M+6.3% | $137.82M+10.9% | $124.27M+5.1% | $118.29M-8.1% | ||
| $141.77M+26.5% | $112.03M+59.3% | $70.34M-36.8% | $111.37M+11.0% | $100.35M+32.4% | ||
| 19.6%+5.9pp | 13.8%+4.8pp | 9%-6.4pp | 15.4%+0.9pp | 14.4%+4.1pp | ||
| -$53.36M+5.1% | -$56.24M+10.5% | -$62.81M+3.5% | -$65.1M-14.3% | -$56.94M+7.7% | ||
| -$61.6M-8.4% | -$56.8M+24.8% | -$75.57M-26.7% | -$59.66M+5.1% | -$62.86M+31.0% | ||
| $80.18M+45.2% | $55.24M+1,158% | -$5.22M-110% | $51.71M+37.9% | $37.49M+345% | ||
| $2.18M-61.6% | $5.66M+124% | -$23.36M-245% | $16.1M+25.1% | $12.87M+137% | ||
| $62.26M+77.5% | $35.08M+1,381% | $2.37M-89.4% | $22.42M+83.8% | $12.2M+139% | ||
| 8.6%+4.3pp | 4.3%+4.0pp | 0.3%-2.8pp | 3.1%+1.3pp | 1.8%+6.0pp | ||
| $0.19+72.7% | $0.11+1,000% | $0.01-85.7% | $0.07+75.0% | $0.04+140% | ||
| $141.77M+26.5% | $112.03M+59.3% | $70.34M-36.8% | $111.37M+11.0% | $100.35M+32.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
- Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.